Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A study conducted by Switzerland's Janssen-Cilag has shown that patients diagnosed with schizophrenia can benefit from a change in treatment regime when prescribed Janssen's own risperidone compound.
Subscribe to our email newsletter
The study was designed to investigate the efficacy and safety of Risperdal Consta (risperidone) in patients with schizophrenia or other psychotic disorders who required a change of treatment. Patients in the study were symptomatically stable but required a change to their existing antipsychotic regimen.
Participants given Risperdal Consta, a long acting injection, showed statistically significant improvements in psychotic symptoms as early as one month after treatment and continued to improve for the remaining six months of the study.
Patient satisfaction with treatment also significantly improved, with the proportion of patients who rated their treatment satisfaction as “very good” increasing from 6% on previous treatment to 31% on risperidone.
Within the trial 72% of patients reported adverse events including insomnia, anxiety, movement disorders and exacerbation of disease. The severity of extrapyramidal side effects were significantly reduced relative to baseline after one month of treatment, and further improvements were seen until treatment endpoint.
Overall, patients experienced a mean weight gain of 2.3 pounds from baseline to endpoint and five patients had a treatment-emergent glucose-related adverse event, including three cases of new-onset diabetes mellitus.